Key result
Ripple mapping-guided isthmus ablation is being evaluated against conventional ablation for the treatment of scar-related atrial tachycardia in this ongoing randomized controlled trial.
Why the study?
Conventional ablation creates extensive anatomical lines that can serve as a nidus for recurrence, whereas high-density ripple mapping can identify narrower isthmuses requiring less ablation.
Does ripple mapping-guided isthmus ablation reduce recurrence of any atrial arrhythmia in patients with scar-related atrial tachycardia compared to conventional ablation?
RCT (n=200)
Single-blind
1:1
Yes
Does ripple mapping-guided isthmus ablation reduce recurrence of any atrial arrhythmia in patients with scar-related atrial tachycardia compared to conventional ablation?
This trial protocol outlines a study to determine if targeting narrower isthmuses using ripple mapping improves long-term freedom from arrhythmia recurrence in scar-related atrial tachycardia compared to conventional ablation.
Answers are grounded in this paper and cite their sources.
May allow less extensive ablation via ripple mapping in scar-related AT; leaves open whether it reduces recurrence versus lines in randomized trials.
Background Catheter ablation is routinely used to treat scar-related atrial tachycardia (s-AT). Conventional ablation often involves creating anatomical “lines” that transect myocardial tissue supporting reentry. This can be extensive, creating iatrogenic scar as a nidus for future reentry, and may account for arrhythmia recurrence. High-density mapping may identify “narrower isthmuses” requiring less ablation, with ripple mapping proven to be an effective approach in identifying. This trial explores whether ablation of narrower isthmuses in s-AT, defined using ripple mapping, results in greater freedom from arrhythmia recurrence compared to conventional ablation. Methods The Ripple-AT-Plus trial (registration ClinicalTrials.gov , NCT03915691) is a prospective, multicentre, single-blinded, randomised controlled trial with 12-month follow-up. Two hundred s-AT patients will be randomised in a 1:1 fashion to either “ripple mapping-guided isthmus ablation” vs conventional ablation on the CARTO3 ConfiDENSE system (Biosense Webster). The primary outcome will compare recurrence of any atrial arrhythmia. Multicentre data will be analysed over a secure web-based cloud-storage and analysis software (CARTONET TM ). Conclusion This is the first trial that considers long-term patient outcomes post s-AT ablation, and whether targeting narrower isthmuses in the era of high density is optimal.
No takes yet. Share an insight, caveat, or question.
Kailey et al. (2023) conducted an RCT in Scar-related atrial tachycardia (n=200). Ripple mapping-guided isthmus ablation vs. Conventional mapping and ablation was evaluated on Recurrence of any atrial arrhythmia (>30 s) at any time in the 12-month period after a 2-month blanking period. Ripple mapping-guided isthmus ablation is being evaluated against conventional ablation for the treatment of scar-related atrial tachycardia in this ongoing randomized controlled trial.
Synapse has enriched 10 related papers. Consider them for comparative context: